RhumbLine Advisers’s Blueprint Medicines BPMC Stock Holding History

RhumbLine Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-99,649	Closed	-$12.8M	–	4127
2025 Q2	$12.8M	Buy	99,649 +7,716	+8%	+$801K	0.01%	952
2025 Q1	$8.14M	Buy	91,933 +5,402	+6%	+$527K	0.01%	1110
2024 Q4	$7.55M	Sell	86,531 -1,318	-2%	-$121K	0.01%	1205
2024 Q3	$8.13M	Sell	87,849 -3,694	-4%	-$367K	0.01%	1168
2024 Q2	$9.87M	Buy	91,543 +5,160	+6%	+$516K	0.01%	1025
2024 Q1	$8.19M	Buy	86,383 +2,017	+2%	+$173K	0.01%	1149
2023 Q4	$7.78M	Sell	84,366 -836	-1%	-$54.2K	0.01%	1179
2023 Q3	$4.28M	Buy	85,202 +1,332	+2%	+$71.2K	0.01%	1453
2023 Q2	$5.3M	Buy	83,870 +2,637	+3%	+$143K	0.01%	1341
2023 Q1	$3.65M	Buy	81,233 +226	+0.3%	+$10.2K	﹤0.01%	1488
2022 Q4	$3.55M	Buy	81,007 +1,653	+2%	+$79.3K	﹤0.01%	1483
2022 Q3	$5.23M	Buy	79,354 +7,246	+10%	+$465K	0.01%	1205
2022 Q2	$3.64M	Buy	72,108 +8,674	+14%	+$508K	0.01%	1436
2022 Q1	$4.05M	Buy	63,434 +924	+1%	+$66.3K	0.01%	1446
2021 Q4	$6.7M	Sell	62,510 -1,347	-2%	-$141K	0.01%	1198
2021 Q3	$6.57M	Buy	63,857 +1,180	+2%	+$110K	0.01%	1183
2021 Q2	$5.51M	Buy	62,677 +463	+0.7%	+$42.4K	0.01%	1372
2021 Q1	$6.05M	Sell	62,214 -7,668	-11%	-$766K	0.01%	1304
2020 Q4	$7.84M	Buy	69,882 +1,897	+3%	+$200K	0.01%	1083
2020 Q3	$6.3M	Sell	67,985 -17,029	-20%	-$1.31M	0.01%	1019
2020 Q2	$6.63M	Buy	85,014 +9,004	+12%	+$609K	0.01%	1025
2020 Q1	$4.45M	Buy	76,010 +4,902	+7%	+$315K	0.01%	1092
2019 Q4	$5.7M	Buy	71,108 +3,058	+4%	+$229K	0.01%	1176
2019 Q3	$5M	Sell	68,050 -216	-0.3%	-$18.7K	0.01%	1181
2019 Q2	$6.44M	Buy	68,266 +13,458	+25%	+$1.11M	0.01%	1061
2019 Q1	$4.39M	Sell	54,808 -541	-1%	-$40K	0.01%	1255
2018 Q4	$2.98M	Buy	55,349 +17,475	+46%	+$1.06M	0.01%	1410
2018 Q3	$2.96M	Sell	37,874 -2,585	-6%	-$180K	0.01%	1440
2018 Q2	$2.57M	Sell	40,459 -460	-1%	-$36.6K	0.01%	1530
2018 Q1	$3.75M	Buy	40,919 +8	+0%	+$690	0.01%	1238
2017 Q4	$3.08M	Sell	40,911 -4,122	-9%	-$290K	0.01%	1359
2017 Q3	$3.14M	Buy	45,033 +1,329	+3%	+$71K	0.01%	1323
2017 Q2	$2.21M	Buy	43,704 +16,825	+63%	+$714K	0.01%	1516
2017 Q1	$1.07M	Buy	26,879 +5,605	+26%	+$201K	﹤0.01%	1875
2016 Q4	$597K	Buy	21,274 +1,363	+7%	+$41.1K	﹤0.01%	2131
2016 Q3	$591K	Buy	19,911 +3,670	+23%	+$91.2K	﹤0.01%	2100
2016 Q2	$329K	Buy	+16,241	New	+$295K	﹤0.01%	2472
2016 Q1	–	Sell	-9,057	Closed	-$239K	–	2995
2015 Q4	$239K	Buy	+9,057	New	+$204K	﹤0.01%	2701
2015 Q3	–	Sell	-7,710	Closed	-$204K	–	3010
2015 Q2	$204K	Buy	+7,710	New	+$220K	﹤0.01%	2885

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

RhumbLine Advisers's BPMC Position: Q3 2025 in Review

RhumbLine Advisers sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 99,649 shares — an estimated $12.8M sold.

RhumbLine Advisers first reported a position in BPMC in Q2 2015 and held it in 39 quarters. The position peaked at $12.8M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

RhumbLine Advisers reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
RhumbLine Advisers sold 99,649 Blueprint Medicines shares in Q3 2025, an estimated $12.8M.
RhumbLine Advisers first reported a position in Blueprint Medicines in Q2 2015 and held it in 39 quarters.
RhumbLine Advisers's Blueprint Medicines position peaked at $12.8M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.